...
首页> 外文期刊>Chemistry of Materials: A Publication of the American Chemistry Society >Leveraging Spectral Matching between Photosensitizers and Upconversion Nanoparticles for 808 nm-Activated Photodynamic Therapy
【24h】

Leveraging Spectral Matching between Photosensitizers and Upconversion Nanoparticles for 808 nm-Activated Photodynamic Therapy

机译:利用光敏剂和上转换纳米颗粒之间的光谱匹配,用于808nm活化的光动力学治疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Upconversion nanoparticles (UCNPs) are promising platforms to enhance the therapeutic response of cancer cells toward photodynamic therapy (PDT). When coupled with UCNPs, the photosensitizers in PDT are indirectly activated by near-infrared (NIR) excitation that allows for deeper tissue penetration and reduced attenuation. To achieve maximum performance, the upconverted emission peak of the UCNPs and absorption band of the photosensitizers need to overlap significantly. However, the spectral mismatch between the upconverted emission maximum of UCNPs (predominantly in the green) and absorption maximum of most available photosensitizers (in the red) greatly limits the therapeutic efficacy of current UCNP-PDT platforms. Here we report a UCNP-PDT platform that under biobenign 808 nm NIR excitation shows a strong spectral overlap between the UCNP emission (lambda(em)) and absorption of zinc phthalocyanine photosensitizers . ( lambda(abs)) . The spectrally matched UCNP red emission band is 40 times stronger than the green emission band and is independent of laser excitation power across a wide range (0.6-3.4 W/cm(2)) applicable in biological systems. The spectrally matched UCNP-PDT platform enables rapid generation (5 min) of cytotoxic singlet oxygen via near-infrared excitation at extremely low laser power density of only 0.6 W/cm(2) . Finally, we show that the actively growing HeLa cancer cell spheroids with 3 mm diameter can be effectively suppressed with 65% drop of the cell viability, demonstrating the suitability and effectiveness of the spectrally matched UCNP-PDT platforms for cancer therapeutics.
机译:上转化纳米颗粒(UCNP)是有前途平台,以增强癌细胞对光动力治疗(PDT)的治疗响应。当与UCNP耦合时,PDT中的光敏剂通过近红外(NIR)激发间接激活,其允许更深的组织渗透和减少衰减。为了实现最大性能,UCNP的上变频峰值和光敏剂的吸收带的放射峰需要显着重叠。然而,UCNP的上络发射最大值之间的光谱失配(主要在绿色)和最大值最多的最多可用的光敏剂(红色)大大限制了当前UCNP-PDT平台的治疗效果。在这里,我们报告了一个UCNP-PDT平台,在BiobeniCn 808 nm NiR激发下显示UCNP发射(Lambda(EM))与锌酞菁光敏剂的吸收之间的强烈光谱重叠。 (λ(ABS))。光谱匹配的UCNP红色发射带的比绿色发射带更强,并且与适用于生物系统的宽范围(0.6-3.4W / cm(2))的激光激发电力无关。光谱匹配的UCNP-PDT平台通过极低的激光功率密度为0.6W / cm(2),通过近红外激发快速发电(5分钟)细胞毒性单态氧。最后,我们表明,通过65%的细胞活力可以有效地抑制了具有3mm直径的积极生长的Hela癌细胞球体,并展示了癌症治疗剂的光谱匹配的UCNP-PDT平台的适用性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号